JFP- News today on BIPL, an old Bowser pick. Also, he addressed the recent insider selling in the last newsletter. The guy who sold started his own biz, so needed the $$$$ BIPL seems very cheap right now. WJ
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>Wednesday July 16 6:30 AM EDT
Company Press Release
Biopool International Enters Into Four New Distribution
Agreements
VENTURA, Calif.--(BUSINESS WIRE)--July 16, 1997--Biopool International
(NASDAQ:BIPL) Wednesday announced that the company has entered into new agreements for
the distribution of its BCA immunohematology products in Germany, the United Kingdom, the
Caribbean and Croatia/Slovenia.
A new distribution agreement in Germany was entered into with Organon Teknika Germany,
which had been distributing the BCA immunohematology (blood group serology) product line prior
to Biopool's acquisition of the division from Organon Teknika. This new agreement, however,
ensures continuity of this business in Germany, currently the largest export market for the BCA
product line.
In the United Kingdom, Bio-Stat Ltd. has been appointed as the new distributor of BCA
immunohematology products. Bio-Stat has been distributing Biopool hemostasis products for the
past five years and, with this new agreement, has now extended its available product line to include
BCA products.
Biopool has also entered into an agreement with F. Baragano Pharmaceuticals Inc. to distribute
both immunohematology and hemostasis products in the territory of the Caribbean. Based in
Puerto Rico, F. Baragano is an established and well-known supplier in the territory, handling a
wide range of diagnostic reagents.
In the territory of Croatia and Slovenia, Biopool has appointed Kalba d.o.o. as the company's
new distributor of immunohematology products.
Michael D. Bick, Ph.D., chairman and chief executive officer of Biopool, stated: ``These
agreements signal our continuing efforts to assure continuity of the immunohematology business, as
in the case of Organon Teknika Germany, and to establish new dealers to expand our presence
and market share worldwide. Numerous other agreements are under discussion and are expected
to be finalized in the coming months.''
Founded in 1987, Biopool International develops, manufactures and markets a full range of test
kits to assess and diagnose disorders of blood coagulation, thrombotic risk factors, fibrinolysis,
platelet function and the vascular system; specialty chemistry controls used to monitor and measure
the presence of drugs of abuse; and blood group serology products used to screen for antibodies
and group and type whole blood.
The company's product line of more than 150 FDA-approved products are sold to hospitals,
blood bank facilities, and clinical and reference laboratories on a worldwide basis through an
extensive network of distributors.
Contact:
Biopool International Inc., Ventura
Michael D. Bick/Carol Hill, 805/654-0643 |
